Skip Navigation LinksHome > March 2009 - Volume 28 - Issue 3 > EFFICACY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-B...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31818dd72b
Brief Reports

EFFICACY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN THAI HIV-INFECTED CHILDREN AGED TWO YEARS OR LESS

Puthanakit, Thanyawee MD*; Aurpibul, Linda MD*; Sirisanthana, Thira MD*; Sirisanthana, Virat MD†

Collapse Box

Abstract

Twenty-six Thai HIV-infected children, aged 2 years or less were prospectively enrolled to receive non-nucleoside reverse transcription inhibitor-based highly active antiretroviral therapy (HAART). Twenty-two children (85%) had World Health Organization clinical stage 3 or 4. The median baseline CD4 cell percentage and plasma HIV RNA were 17% and 5.9 log 10 copies/mL, respectively. The median age at HAART initiation was 9.8 months (range, 1.5–24.0). One child died. The mean CD4 cell percentages at 24, 48, and 96 weeks of treatment were 26%, 31%, and 37%, respectively. The proportions of children with virologic suppression (<400 copies/mL) at week 24 and 48 were 14/26 (54%) and 19/26 (73%), respectively. Non-nucleoside reverse transcription inhibitor-based HAART is safe and effective in HIV-infected young children in a resource-limited setting.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.